Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole

British Journal of Clinical Pharmacology, Supplement

Volumn 56, Issue 1, 2003, Pages 51-55

  Purkins, Lynn ^a   Wood, Nolan ^a   Kleinermans, Diane ^b   Nichols, Don ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Cimetidine; Drug interaction; Pharmacokinetics; Ranitidine; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; CIMETIDINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE; VORICONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; VISUAL DISORDER; DRUG COMBINATION; DRUG INTERACTION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; CIMETIDINE; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; PYRIMIDINES; RANITIDINE; TRIAZOLES;

EID: 0344512407     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01999.x     Document Type: Article

References (18)

1. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531-533.
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
3. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today 2001; 37: 135-148.
4. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 305, September 2000.
5. Perfect J, Gonzalez-Ruiz A, Lutsar I. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 303, September 2000.
6. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
7. Koltin Y, Hitchcock CA. Progress in the search for new triazole antifungal agents. Curr Opin Chem Biol 1997; 1: 176-182.
8. Patterson BE, Coates PE. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F78, September 1995.
9. Patterson BE, Roffey S, Jezequel SG, Jones B. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F79, September 1995.
10. Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol 1990; 12 (Suppl. 2): S54-S63.
11. Rendic S, Kajfez F, Ruf H-H. Characterization of cimetidine, ranitidine, and related structures interaction with cytochrome P-450. Drug Metab Dispos 1983; 11: 137-142.
12. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl 1997; 691: 441-448.
13. SAS/STAT User's Guide, Version 6, 4th edn. Cary, NC: SAS Institute Inc., 1989.
14. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56 (Suppl. 1): 10-16.
15. 2-receptor antagonists on drug interaction in rats. Drug Metab Dispos 1986; 14: 649-653.
16. 2- receptor antagonists. Clin Pharmacol Ther 1999; 65: 369-376.
17. Washton H. Review of fluconazole: a new triazole antifungal agent. Diagn Microbiol Infect Dis 1989; 12 (Suppl.): 229S-233S.
18. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990; 12 (Suppl. 3): S327-S333.